Search Results
Dec 18, 2025, 14:26 ET ANVISA aprova Metalyse® 25mg da Boehringer Ingelheim para o tratamento de AVC isquêmico agudo
S, et al. Eur Stroke J. 2023; 8(1): 8-54.Warach SJ and Saver JL. JAMA Neurol. 2020;77(10): 1203-1204.Heran M, et al. Can J Neurol Sci. 2022; 19: 1-94.Stroke Foundation. Diretrizes clínicas para tratamento de AVC de 2017. Disponível em:
More news about: Boehringer Ingelheim
Dec 18, 2025, 13:00 ET Amphix Bio raises $12.5M seed round to advance peptide drug platform
two products. Amphix Bio secured Orphan Drug Designation for AMFX-200, its lead neurological candidate, for the treatment of acute spinal cord injury (SCI). The team also completed a Type C meeting with the U.S. Food and Drug Administration (FDA), receiving constructive feedback on preclinical safety studies
More news about: Amphix Bio
Dec 18, 2025, 06:45 ET Lilly's orforglipron helped people maintain weight loss after switching from injectable incretins to oral GLP-1 therapy in first-of-its-kind Phase 3 trial
Kobilka, & K.W. Sloop, Structural basis for GLP-1 receptor activation by LY3502970, an orally active nonpeptide agonist, Proc. Natl. Acad. Sci. U.S.A. 117 (47) 29959-29967,
More news about: Eli Lilly and Company
Dec 17, 2025, 21:18 ET The Second Silk Fashion Gala Opens at China National Silk Museum
highlight ahead of the 55th anniversary of diplomatic ties between the two countries. Co‑organized by the China National Silk Museum and Zhejiang Sci‑Tech University, it featured 32 young designers from China and Italy who transformed textile heritage into modern fashion. Over 70 original designs were
More news about: China National Silk Museum
Dec 15, 2025, 12:04 ET Africa Emerges as Gold's Next Supply Engine Amid Record Prices and Development Wave
been approved by Lake Victoria Gold Ltd. Technical information relating to Lake Victoria Gold Ltd. has been reviewed and approved by David Scott, Pr. Sci. Nat., a Qualified Person as defined by National Instrument 43-101. Mr. Scott is a registered member of the South African Council for Natural Scientific
More news about: USA News Group
Dec 12, 2025, 04:49 ET People's Daily Online: Guangming Science City Forum 2025 held in S China's Shenzhen
platforms, including automated biomanufacturing, large-scale vector production, and quality-control facilities.At the forum, the Shenzhen Guangming Sci-Tech Innovation Fund of Funds was launched, with an initial capital commitment of approximately 1 billion yuan ($140 million).The forum also marked
More news about: People's Daily Online
Dec 10, 2025, 12:24 ET Jiangyin concluye el mes de inversión de otoño dorado con 208 proyectos por un total de 68.000 millones de yuanes
instituciones académicas y de investigación nacionales para formar la Alianza Universitaria para la Transferencia y la Comercialización de Tecnología "Sci-tech Innovations in Jiangyin" (Innovaciones científicas y tecnológicas en Jiangyin). La alianza tiene como objetivo desarrollar nuevos modelos para transformar
More news about: Jiangyin Municipal Committee and Government
Dec 10, 2025, 04:35 ET IITM Pravartak in Partnership With Simplilearn, Launches 'The Smart Shield: AI-Powered Cybersecurity Mastery Program'
benefit from certifications such as Microsoft Certified: Azure AI Fundamentals (AI-900) and Microsoft Certified: Security, Compliance, and Identity (SCI) Fundamentals (SC-900) will deepen understanding of cognitive services and data protection within Microsoft ecosystems.Speaking about the program,
More news about: Simplilearn Solutions Private Limited
Dec 09, 2025, 22:43 ET Jiangyin conclut le mois de l'automne doré de l'investissement avec 208 projets totalisant 68 milliards de RMB
institutions universitaires et de recherche nationales pour former l'alliance universitaire pour le transfert et la commercialisation des technologies « Sci-tech Innovations in Jiangyin » . L'alliance vise à développer de nouveaux modèles pour traduire la recherche et les percées technologiques en applications
More news about: Jiangyin Municipal Committee and Government
Dec 09, 2025, 22:41 ET Jiangyin schließt Golden Autumn Investment Month mit 208 Projekten im Gesamtwert von 68 Mrd. RMB ab
inländischen Hochschul- und Forschungseinrichtungen zusammen und gründete die Universitätsallianz für Technologietransfer und Kommerzialisierung, die „Sci-tech Innovations in Jiangyin". Ziel der Allianz ist es, neue Modelle für die Umsetzung von Forschung und technologischen Durchbrüchen in kommerzielle Anwendungen
More news about: Jiangyin Municipal Committee and Government
Dec 09, 2025, 19:26 ET Innovent Announces First Participant Dosed in a Phase 1 Clinical Trial of IBI3011, a Recombinant Anti-Human Interleukin 1 Receptor Accessory Protein Monoclonal Antibody
Med. 2022;10(2):134-145[2]. Sci Rep. 2025;15(1):3310.[3]. Sun
More news about: Innovent Biologics
Dec 09, 2025, 09:00 ET AUTUMN BAILEY ENTERTAINMENT AND TY WALKER'S BRAVEHEART ENTERTAINMENT PARTNER WITH ASSEMBLY STUDIOS TO POWER A NEW ERA OF INDEPENDENT FILMMAKING IN ATLANTA
formats, Braveheart projects are defined by authenticity, innovation, and cross-cultural appeal. Walker's credits include executive producer on the sci-fi feature Xeno and producer on the action film Die Hart for Amazon.
More news about: Universal Studios, Inc.
Dec 09, 2025, 08:30 ET PTC Launches Arena AI Engine to Accelerate Intelligent Automation Across PLM and QMS Workflows
Arena Supply Chain Intelligence (SCI) features, including:Enhancements to the Arena AI Assistant to add support with more Help topics and full multilingual availability,
More news about: PTC Inc.
Dec 09, 2025, 04:37 ET Jiangyin Concludes Golden Autumn Investment Month with 208 Projects Totaling RMB68 Billion
Davide said. During the symposium, Jiangyin joined with Tsinghua University and other domestic academic and research institutions to form the "Sci-tech Innovations in Jiangyin" University Alliance for Technology Transfer and Commercialization. The alliance aims to develop new models for translating
More news about: Jiangyin Municipal Committee and Government
Dec 09, 2025, 04:21 ET Jiangyin Concludes Golden Autumn Investment Month with 208 Projects Totaling RMB68 Billion
Davide said. During the symposium, Jiangyin joined with Tsinghua University and other domestic academic and research institutions to form the "Sci-tech Innovations in Jiangyin" University Alliance for Technology Transfer and Commercialization. The alliance aims to develop new models for translating
More news about: Jiangyin Municipal Committee and Government
Dec 08, 2025, 14:00 ET Tiger BioSciences Highlights Study on Advanced Placental CAMP Technologies
Landa, O.; King, A.R.; Valdes Cavazos, D.; Marquez, J.; Hill, S. Native Wound-Repair Proteins Retained in Multilayer Placental CAMPs. Int. J. Mol. Sci. 2025, 26, 10121.
More news about: Tiger BioSciences
Dec 08, 2025, 12:00 ET Sumitomo Pharma America Presents New Investigational Data on Enzomenib and Nuvisertib at the 2025 American Society of Hematology Annual Meeting and Exposition
doi:10.4155/fmc.13.214Matkar S, Thiel A, Hua X. Menin: a scaffold protein that controls gene expression and cell signaling. Trends Biochem Sci. 2013;38(8):394-402. doi:10.1016/j.tibs.2013.05.005Kühn MW, Song E, Feng Z, et al. Targeting Chromatin Regulators Inhibits Leukemogenic Gene
More news about: Sumitomo Pharma America
Dec 08, 2025, 08:00 ET Adient Formed a Joint Venture with SCI to Drive Growth in China
Dec. 8, 2025 /PRNewswire/ -- Recently, Adient, a global leader in automotive seating, completed the acquisition of a 49% equity stake in SCI (Zhangjiakou) Co., Ltd., a local Chinese supplier under Zhejiang Yoening Technology Group, officially establishing a new strategic joint venture. This
More news about: Adient
Dec 08, 2025, 07:00 ET UCB presents positive results from GEMZ phase 3 study at AES showing fenfluramine significantly reduced countable motor seizure frequency in CDKL5 deficiency disorder
Male. Children (Basel). 2022;9(12):1806.6 Jakimiec M, et al. CDKL5 Deficiency Disorder—A Complex Epileptic Encephalopathy. Brain Sci. 2020;10(2):107.7 Hong W, et al. CDKL5 Deficiency Disorder-Related Epilepsy: A Review of Current and Emerging Treatment. CNS Drugs.
More news about: UCB
Dec 08, 2025, 04:13 ET SJTU International Gen Z Students Explore Shanghai's Innovation Ecosystem
world-class innovation ecosystem (July 9-24). Their firsthand experiences form the foundation of the university's ongoing "Gen Z Perspectives on Shanghai's Sci-Tech Innovation" media initiative. The project documents in-depth stories of AI and smart manufacturing advancements through the students' lens, creating
More news about: Antai College of Economics and Management, Shanghai Jiao Tong University
Dec 08, 2025, 03:57 ET SJTU International Gen Z Students Explore Shanghai's Innovation Ecosystem
world-class innovation ecosystem (July 9-24). Their firsthand experiences form the foundation of the university's ongoing "Gen Z Perspectives on Shanghai's Sci-Tech Innovation" media initiative. The project documents in-depth stories of AI and smart manufacturing advancements through the students' lens, creating
More news about: Antai College of Economics and Management, Shanghai Jiao Tong University
Dec 08, 2025, 01:32 ET UCB presents positive results from GEMZ phase 3 study at AES showing fenfluramine significantly reduces countable motor seizure frequency in CDKL5 Deficiency Disorder
Male. Children (Basel). 2022;9(12):1806.[6] Jakimiec M, et al. CDKL5 Deficiency Disorder—A Complex Epileptic Encephalopathy. Brain Sci. 2020;10(2):107.[7] Hong W, et al. CDKL5 Deficiency Disorder-Related Epilepsy: A Review of Current and Emerging Treatment. CNS Drugs.
More news about: UCB
Dec 08, 2025, 01:28 ET UCB presents positive results from GEMZ phase 3 study at AES showing fenfluramine significantly reduces countable motor seizure frequency in CDKL5 Deficiency Disorder
Male. Children (Basel). 2022;9(12):1806.[6] Jakimiec M, et al. CDKL5 Deficiency Disorder—A Complex Epileptic Encephalopathy. Brain Sci. 2020;10(2):107.[7] Hong W, et al. CDKL5 Deficiency Disorder-Related Epilepsy: A Review of Current and Emerging Treatment. CNS Drugs.
More news about: UCB
Dec 05, 2025, 17:45 ET AL-S Pharma Reports Positive Results from Phase 2 Study of AP-101 for the Treatment of ALS, Supporting Plans for a Confirmatory Phase 3 Study
NCT05039099).1Maier M et al., Sci Transl Med. 2018;10(470).2Marlow TR et al., Neurobiol Dis. 2025;216:107124.About AP-101AP-101 is an investigational
More news about: AL-S Pharma AG
Dec 04, 2025, 11:00 ET Muscles, the New Flex: Abbott Launches Two New Ensure® Max Protein Shakes to Tap into Growing Muscle Health Movement
vCampbell WW, et al. J Gerontol A Biol Sci Med Sci. 2023;78(1):67–72.vi
More news about: Abbott